Combined targeting of the PD-1 and TIM-3 pathways was revealed to be more effective in improving CD8 T cell responses and viral control in chronically viral infected mice [23] and in controlling tumor growth in solid tumor-bearing mice [24]. The gene discussed is HAVCR2; the disease is neoplasm.